The $3.85 million cash infusion provides near-term working capital, but the massive dilution from 2.37 million new warrants at a low $3.25 strike price and the repricing of all existing milestone warrants to the same level signals significant shareholder dilution ahead. Watch for the resale registration statement filing within 15 days and subsequent selling by Armistice Capital, which could pressure the stock. The 30-day equity issuance lockup provides a temporary reprieve from further dilution.
Price Chart
Executive Summary
Decoy Therapeutics entered into a warrant inducement agreement with Armistice Capital Master Fund Ltd. to immediately exercise 1,184,434 Series B Milestone Warrants at a reduced exercise price of $3.25 per share, generating approximately $3.85 million in gross proceeds. As consideration, the company issued 2,368,868 new unregistered warrants (200% of exercised shares) with a $3.25 exercise price and 5-year term. The exercise price of outstanding Series A and Series C Milestone Warrants was also reduced to $3.25. The company received $3.85 million in cash but created significant future dilution with the new warrants, while also reducing the exercise price on all outstanding milestone warrants.
Key Financial Metrics
Key Facts
- Armistice Capital Master Fund Ltd. exercised 1,184,434 Series B Milestone Warrants at $3.25/share for gross proceeds of $3,849,410
- Company issued 2,368,868 new unregistered warrants (200% of exercised shares) with $3.25 exercise price, exercisable immediately, 5-year term
- Exercise price of all outstanding Series A, Series B, and Series C Milestone Warrants reduced from $5.91 to $3.25 per share
- New warrants have cashless exercise provisions and 9.99% beneficial ownership limitation
- Company agreed to file resale registration statement for new warrant shares within 15 days and use best efforts for effectiveness within 45-90 days
- 30-day lockup on further equity issuance; 180-day ban on variable rate transactions after registration effectiveness
- Curvature Securities LLC acted as placement agent
Financial Impact
Gross proceeds of $3.85 million from warrant exercise; potential future dilution of up to 2,368,868 shares from new warrants at $3.25 exercise price; all outstanding milestone warrants repriced to $3.25 from $5.91
Risk Factors
- Potential for significant selling pressure when new warrant shares become registered for resale
- Dilution from 2.37 million new warrants plus repriced existing milestone warrants could substantially increase share count
- Pre-revenue biotech with no disclosed revenue or pipeline milestones; cash runway concerns remain
- 30-day lockup on equity issuance may indicate limited near-term financing options
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001615219-26-000019 |
| Document: dcoy-ex10_1.htm | 0001615219-26-000019 |
| Document: dcoy-20260922.htm | 0001615219-26-000019 |
| Document: dcoy-ex99_1.htm | 0001615219-26-000019 |
| Document: dcoy-ex99_2.htm | 0001615219-26-000019 |
| Document: 0001615219-26-000019-index-headers.html | 0001615219-26-000019 |
| Document: 0001615219-26-000019-index.html | 0001615219-26-000019 |
| Document: 0001615219-26-000019.txt | 0001615219-26-000019 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | EFFECT | $1.17 $0.9100 | ▼ −22.22% | ▼ −22.08% | $0.9700 (−17.09%) |
Oct 7, 2026 19d ago | S-1 | $1.52 $1.23 | ▲ +19.08% | ▲ +18.80% | $0.9700 (+36.18%) |
Sep 23, 2026 4w ago | 8-K | $3.11 $1.86 | ▲ +40.35% | ▲ +39.94% | $0.9700 (+68.81%) |
Aug 4, 2026 11w ago | DEFA14A | $4.19 $3.60 | ▼ −14.08% | ▼ −14.43% | $0.9700 (−76.85%) |
Jul 20, 2026 14w ago | EFFECT | $5.31 $3.74 | ▼ −29.50% | ▼ −29.10% | $0.9700 (−81.72%) |
Jun 29, 2026 17w ago | 8-K | $9.59 $7.25 | ▲ +24.40% | ▲ +25.79% | $0.9700 (+89.89%) |
Jun 25, 2026 17w ago | EFFECT | $5.92 $7.62 | ▲ +28.76% | ▲ +27.20% | $0.9700 (−83.61%) |
Jun 4, 2026 20w ago | DEFA14A | $6.71 $5.90 | ▼ −12.07% | ▼ −9.52% | $0.9700 (−85.54%) |
Apr 30, 2026 25w ago | 10-K/A | $6.05 $6.01 | ▼ −0.66% | ▼ −2.39% | $0.9700 (−83.97%) |
Apr 2, 2026 29w ago | 8-K | $5.80 $5.84 | ▲ +0.69% | ▼ −2.93% | $0.9700 (−83.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers